Form 4: Tyra Biosciences Director Nina S. Kjellson Reports Stock Sales

Director Nina S. Kjellson reported the sale of Tyra Biosciences (TYRA) common stock through indirect holdings via Canaan XI L.P. and 2020+ Co-Investment L.P. Series 7.

Summary

• Nina S. Kjellson, a director of Tyra Biosciences, reported sales of common stock on November 4 and 5, 2024.
• The sales were executed indirectly through Canaan XI L.P. and 2020+ Co-Investment L.P. Series 7.
• On November 4, 2024, 960 shares were sold at a weighted average price of $17.006, and 116 shares were sold at the same price.
• On November 5, 2024, 9,367 shares were sold at a weighted average price of $16.7683, and 1,126 shares were sold at the same price.
• Following these transactions, Canaan XI L.P. beneficially owns 3,802,447 shares, and 2020+ Co-Investment L.P. Series 7 beneficially owns 457,264 shares.

Sentiment

Score: 5

Explanation: This is a neutral report of stock sales by a director, with no inherent positive or negative implications without further context.

Industry Context

Form 4 filings are a routine part of regulatory compliance for corporate insiders and provide transparency into their transactions in the company's stock.

Stakeholder Impact

• Shareholders may be interested in the trading activity of company insiders as an indicator of their confidence in the company's prospects.

Key Dates